Know Cancer

or
forgot password

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer


Phase 2
N/A
N/A
Not Enrolling
Both
Esophageal Cancer

Thank you

Trial Information

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer


Inclusion Criteria:



- Subjects with advanced or Recurrent esophageal cancer who have completed the previous
late phase 2 study (CA139-540) and should have continued therapy with paclitaxel as
the discretion of the investigator

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Adverse event

Outcome Time Frame:

Throughout the study

Safety Issue:

Yes

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

Japan: Pharmaceuticals and Medical Devices Agency

Study ID:

CA139-557

NCT ID:

NCT00971841

Start Date:

March 2008

Completion Date:

April 2012

Related Keywords:

  • Esophageal Cancer
  • Esophageal Diseases
  • Esophageal Neoplasms

Name

Location